The Viaskin Peanut Patch is still being studied in clinical trials. Current treatment options for peanut allergy are limited. Peanut allergy is common with increasing prevalence reported. Peanut allergy only resolves in approximately 20% of children, otherwise it remains lifelong.
Currently the only FDA approved treatment for peanut allergy is Palforzia.
We have written previously about the Viaskin Peanut Patch being developed by DBV Technologies, VP250. It works by epicutaneous immunotherapy by inducing immune properties of the skin delivering microgram amounts of peanut. Viaskin Peanut Patch (DBV712) 250 micrograms (VP250) has undergone safety and efficacy trials in phase 2 and 3 studies.
In a recent study published titled “Safety of Epicutaneous Immunotherapy in Peanut Allergic Children: REALISE Randomized Clinical Trial Results”, researchers examined the safety in children, using a study design approximating potential real-world use.
REAL LIfe Use and Safety of EPIT (REALISE), is a 6 month study of children aged 4-11 with a diagnosis of peanut allergy receiving daily treatment of the Viaskin Peanut Patch (VP250) up to 36 months.
The results were as follows:
- 396 children with peanut allergy were enrolled and they randomized to receive 3:1 of VP250 of the Viaskin Peanut Patch
- All participants receiving VP250 and 83.8% receiving placebo reported at least 1 episode of local skin reaction, with frequency decreasing over time.
- Only 1.4% of participants receiving the Viaskin Peanut Patch discontinued because of adverse events.
- Epinephrine was administered in 2.4% of participants receiving VP250, none involved severe anaphylaxis.
The Peanut Patch seems to be well tolerated in peanut allergic children. This study had no efficacy assessment and more results will be needed in the future if this gets FDA approval. But peanut allergy is an ongoing challenge as accidental ingestion remains problematic and it is a significant source of stress for children and their families.
Having options available for peanut desensitization would be welcome for doctors and their patients besides oral immunotherapy (OIT) which can have a higher rate of reactions.